SCHEDULE: State Street Discloses 5.2% Stake in Soleno Therapeutics

State Street Corporation has reported beneficial ownership of 5.2% of Soleno Therapeutics Inc.'s common stock as of March 31, 2026.

Summary

• State Street Corporation has filed a Schedule 13G, indicating it beneficially owns 2,680,802 shares of Soleno Therapeutics Inc. common stock.
• This ownership represents 5.2% of the class of securities.
• The filing date for this event is March 31, 2026.
• State Street Corporation holds shared power to vote or direct the vote for 2,544,726 shares and shared power to dispose or direct the disposition of 2,680,802 shares.
• The company's subsidiaries involved in this reporting include SSGA FUNDS MANAGEMENT, INC., STATE STREET GLOBAL ADVISORS EUROPE LIMITED, STATE STREET GLOBAL ADVISORS LIMITED, STATE STREET GLOBAL ADVISORS TRUST COMPANY, and STATE STREET GLOBAL ADVISORS, LTD.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a standard disclosure of institutional ownership and does not provide new operational or financial performance information.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding future performance.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures by institutional investors and investment management firms when their ownership in a public company crosses a certain threshold (typically 5%). This filing by State Street Corporation indicates a significant institutional interest in Soleno Therapeutics Inc.

Stakeholder Impact

• Shareholders: The filing indicates a significant institutional investor, State Street Corporation, holds a 5.2% stake, which can influence market perception and potentially stock liquidity.

Key Dates

Keywords

Schedule 13G, State Street Corporation, Soleno Therapeutics Inc., Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing